National Institute of Allergy & Infectious Diseases (NIAID)
31 Center Drive MSC 2520
Building 31, Room 7A-50
Bethesda
Maryland
20892-2520
United States
Tel: 301-496-5717
Website: http://www.niaid.nih.gov/
302 articles about National Institute of Allergy & Infectious Diseases (NIAID)
-
Siolta Therapeutics Awarded NIH Grant
2/9/2022
Siolta Therapeutics today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Disease.
-
ImmunityBio shared positive results from its clinical trial on its IL-15 superagonist Anktiva (N-803) to treat people living with human immunodeficiency virus (HIV).
-
A recent study estimates that in the U.S. alone the vaccines saved 1.1 million lives and prevented 10.3 million hospitalizations. For that and more COVID-19 news, continue reading.
-
ATCC Announces Award from National Institute of Allergy and Infectious Diseases (NIAID) to Develop Research Capabilities in Infectious, Immunologic and Allergic Diseases
11/23/2021
ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded a seven-year, Indefinite Delivery/Indefinite Quantity contract with a ceiling value of $545 million by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
-
Researchers have published a study of a woman being called the "Esperanza patient," one of what researchers call "elite controllers," who seem to eradicate HIV naturally.
-
If the panel votes in favor of the vaccine for children, it will move to the U.S. CDC. If both agencies support the data, children this age would be likely to receive their first shots in early November.
-
With expectations that the U.S. FDA will announce a decision about booster shots for the Moderna and Johnson & Johnson vaccines this week, there is plenty of COVID-19-related news. Here’s a look.
-
Concerns about Mu and Lambda are growing, but data suggests that Delta is still the biggest problem. The U.S. is also struggling with infections this year. Here’s the latest news.
-
Heading into the Labor Day weekend in the U.S., there’s still plenty of COVID-19 news. Here’s a look.
-
Early data from a Phase III study for COVID-19 shows significant promise with its combo therapy reduced death and hospitalization in trial patients at high risk of progression by 78%.
-
President Biden is expected to be briefed on the lab leak theory conducted over the last 90 days. Very few expect solid results, although this might provide direction for more lines of inquiry.
-
Republican Senator Rand Paul is under fire from government watchdogs for failing to properly disclose a $15,000 purchase of Gilead Sciences stock made by his wife last year.
-
Rep. Michael McCaul issued a third installment today into the origins of the COVID-19 virus and blames the pandemic on a leak from the Wuhan Institute of Virology in China.
-
New data continues to emerge that seems to add to the possibility of COVID-19 originating from a lab leak at China’s Wuhan Institute of Virology.
-
Kytopen Awarded NIH Grant of Up to $2M to Unlock the Power of Engineered Natural Killer (NK) Cells via Flowfect® Platform
6/16/2021
NIH/NIAID SBIR Fast Track grant accelerates the company’s commercial activities towards a non-viral delivery platform that alleviates current limitations on NK cell gene editing
-
Fauci E-mails Raise Critical Questions, States the Association of American Physicians and Surgeons (AAPS)
6/3/2021
Controversy has erupted concerning the thousands of emails to and from Dr. Anthony Fauci that were released in response to Freedom of Information Act requests from Buzzfeed and the Washington Post.
-
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
-
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
-
Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206
5/17/2021
The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206
-
COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in Hamsters and More
4/20/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 20, 2021.